Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Account Payables (2021 - 2025)

Verrica Pharmaceuticals has reported Change in Account Payables over the past 5 years, most recently at $487000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at $487000.0 for Q4 2025, down 47.69% from a year ago — trailing twelve months through Dec 2025 was $176000.0 (up 130.99% YoY), and the annual figure for FY2025 was $176000.0, up 130.99%.
  • Change in Account Payables for Q4 2025 was $487000.0 at Verrica Pharmaceuticals, up from -$736000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for VRCA hit a ceiling of $1.5 million in Q2 2023 and a floor of -$1.4 million in Q2 2024.
  • Median Change in Account Payables over the past 5 years was $69500.0 (2021), compared with a mean of $98400.0.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 1580.0% in 2022 and later tumbled 971.15% in 2025.
  • Verrica Pharmaceuticals' Change in Account Payables stood at -$25000.0 in 2021, then skyrocketed by 1580.0% to $370000.0 in 2022, then soared by 56.22% to $578000.0 in 2023, then skyrocketed by 61.07% to $931000.0 in 2024, then crashed by 47.69% to $487000.0 in 2025.
  • The last three reported values for Change in Account Payables were $487000.0 (Q4 2025), -$736000.0 (Q3 2025), and $878000.0 (Q2 2025) per Business Quant data.